...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cytokine >Increased expression of Interleukin-18 receptor in blood cells of subjects with Mild Cognitive Impairment and Alzheimer's disease
【24h】

Increased expression of Interleukin-18 receptor in blood cells of subjects with Mild Cognitive Impairment and Alzheimer's disease

机译：患有轻度认知障碍和阿尔茨海默病的受试者血细胞中白细胞介素-18受体的表达

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Inflammation has been proposed as a leading force in neurodegeneration and Interleukin (IL)-18 is a pro-inflammatory cytokine which is suggested to be implicated in Alzheimer's disease (AD). However, the meaning of the IL-18 participation in this disease is still unclear. Since IL-18 activity is mediated by its heterodimeric receptor complex IL-18R??/??, we evaluated the presence of both IL-18R chains on peripheral blood cells of AD patients, as well as in individuals with Mild Cognitive Impairment (MCI), at increased risk to develop AD. More specifically, we compared the levels of CD14+ monocytes and CD3+ T-lymphocytes bearing IL-18R?? and ?? chains in the two groups of patients with those in healthy control subjects, both before and after in vitro cell treatment with lipopolysaccharide (LPS).While no differences in the levels of monocytes and T-lymphocytes bearing IL-18R?? chain were found among the three groups, either in untreated and LPS-treated conditions, the IL-18R?? chain expression appeared differently regulated in MCI and AD patients, as compared to controls. In particular, the amount of IL-18R??-bearing monocytes was similar among the three groups at unstimulated conditions, while after LPS treatment it was increased in MCI vs. controls. A significant increase of IL-18R??-bearing T-lymphocytes was also observed in MCI and AD vs. controls, both in untreated and LPS-stimulated conditions. Our findings indicate that the expression of IL-18R complex on blood cells is perturbed in AD and even more markedly in its preclinical state of MCI, confirming that an increased peripheral activity of IL-18 may be involved in the early phase of AD pathophysiology. ? 2012 Elsevier Ltd.
机译：已提出炎症作为神经变性的主要力量，白细胞介素（IL）-18是一种促炎细胞因子，该细胞因子建议涉及阿尔茨海默病（AD）。然而，IL-18参与这种疾病的含义尚不清楚。由于IL-18活性由其异二聚酯受体复合物IL-18R介导的，我们评估了AD患者的外周血细胞上的IL-18R链的存在，以及具有轻度认知障碍的个体（MCI ），增加风险开发广告。更具体地，我们比较了轴承IL-18R的CD14 +单核细胞和CD3 + T淋巴细胞的水平。和 ？？两组患者在两组患者中，在健康对照受试者中，在体外细胞治疗之前和之后用脂多糖（LPS）。携带IL-18R的单核细胞和T淋巴细胞的水平没有差异。在三组中发现链条，无论是在未处理和LPS处理的条件下，IL-18R吗??与对照相比，MCI和AD患者的链表达出现不同。特别地，在未刺发的条件下三组中，轴承的单核细胞的量相似，同时在LPS处理之后，在MCI与对照中增加。在未处理和LPS刺激的条件下，在MCI和AD对照中也观察到IL-18R的显着增加。我们的研究结果表明，在血细胞上的IL-18R复合物的表达在Ad中扰动，并且在其临床前的MCI中甚至更明显，证实IL-18的外周活性增加可以参与AD病理生理学的早期阶段。还2012年elestvier有限公司

著录项

  • 来源
    《Cytokine》 |2013年第2期|共4页
  • 作者

    SalaniF.; CiaramellaA.; BizzoniF.; AssognaF.; CaltagironeC.; SpallettaG.; BossùP.;

  • 作者单位

    Department of Clinical and Behavioral Neurology IRCCS Santa Lucia Foundation Via Ardeatina 306 I;

    Department of Clinical and Behavioral Neurology IRCCS Santa Lucia Foundation Via Ardeatina 306 I;

    Department of Clinical and Behavioral Neurology IRCCS Santa Lucia Foundation Via Ardeatina 306 I;

    Department of Clinical and Behavioral Neurology IRCCS Santa Lucia Foundation Via Ardeatina 306 I;

    Department of Clinical and Behavioral Neurology IRCCS Santa Lucia Foundation Via Ardeatina 306 I;

    Department of Clinical and Behavioral Neurology IRCCS Santa Lucia Foundation Via Ardeatina 306 I;

    Department of Clinical and Behavioral Neurology IRCCS Santa Lucia Foundation Via Ardeatina 306 I;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 细胞生物学;
  • 关键词

    Alzheimer's disease; IL-18 receptor chains; Mild Cognitive Impairment; Monocytes; T-lymphocytes;

    机译：阿尔茨海默病;IL-18受体链;轻度认知障碍;单核细胞;T淋巴细胞;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号